Neurogene Reports Promising Interim Results for NGN-401 Trial

Neurogene ( (NGNE) ) just unveiled an update.

Neurogene Inc. has reported promising interim results from its Phase 1/2 trial of NGN-401 gene therapy for Rett syndrome, highlighting improvements in key areas like motor skills and communication among the first four low-dose pediatric participants. The therapy, which has shown a favorable safety profile, marks significant progress as it addresses the core symptoms of this challenging neurodevelopmental disorder. The company plans to continue the trial with an adolescent/adult cohort and anticipates further updates in 2025, potentially paving the way for a commercial launch.

For detailed information about NGNE stock, go to TipRanks’ Stock Analysis page.